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Abstract
After treatment for a non-functioning pituitary adenoma (NFA) health-related quality of life (HR-QoL) improves consider-
ably. However, the literature about the normalization of HR-QoL after treatment is inconclusive. Some researchers described 
a persistently decreased HR-QoL compared to reference data, while others did not. Considering this variety in observed 
HR-QoL outcomes, the aim of the present review was to provide a literature overview of health outcomes in patients with a 
NFA, using a conceptual HR-QoL model. A concrete conceptualization of the health outcomes of patients with a NFA can be 
helpful to understand the observed variety in HR-QoL outcomes and to improve clinical care and guidance of these patients. 
For this conceptualization, the Wilson and Cleary model was used. This model has a biopsychosocial character and has been 
validated in several patient populations. In the present review, health outcomes of patients with a NFA were described at each 
stage of the model e.g. biological and physiological variables, symptom status, functional status, general health perceptions 
and overall HR-QoL. The Wilson–Cleary model elucidates that elements at each stage of the model can contribute to the 
impairment in HR-QoL of patients with a NFA, which explains the reported variety in the literature. Furthermore, by apply-
ing the model, potential interventions targeting these elements can be identified. While optimal biomedical treatment has 
always been the focus, it is clearly not sufficient for good HR-QoL in patients with a NFA. Further improvement of HR-QoL 
should be supported by a pituitary specific care trajectory, including psychosocial care (e.g. self-management training), to 
beneficially affect characteristics of the patient and the (healthcare) environment, with the utmost goal to optimize HR-QoL 
in patients after treatment.
Keywords Quality of life · QoL · Health-related quality of life · HR-QoL · Well-being · Patient reported outcome · Pituitary 
adenoma · Non-functioning pituitary adenoma · Wilson–Cleary model
Background
Pituitary adenomas are benign tumours, with an estimated 
prevalence of 78–94 cases per 100,000 individuals, and an 
incidence of four cases per 100,000 individuals [1]. Ten per-
cent of all pituitary adenomas are non-functional adenomas 
(NFAs) [2]. NFAs commonly occur during adulthood with 
a median age at diagnosis of 51.5 years (range 19–79 years) 
[3]. At time of diagnosis, tumour size is relatively large 
compared to functioning tumours, since hormone excesses 
are absent, and therefore mainly manifest via compression 
of surrounding tissues, predominantly compression on the 
optic chiasm. Primary treatment consists of surgical resec-
tion of the tumour to relieve mass effects. Conventional 
radiotherapy may be used in case of tumour growth or when 
surgical resection is not an option due to the localization [2]. 
After treatment, patient reported health-related quality of life 
(HR-QoL) improves considerably (Fig. 1) [4], however, the 
evidence about normalization of HR-QoL is inconclusive. 
While some researchers described a persistent decreased 
HR-QoL compared to healthy controls and reference data 
[5, 6], others did not [7, 8].
Furthermore, the cause of the persistent impairments in 
HR-QoL seems to be multifactorial and several contribut-
ing factors have been reported, including visual function, 
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type of surgery (craniotomy vs. transsphenoidal), hypopi-
tuitarism, and the need for hormone replacement therapy 
[4].
The aim of the present review was to provide an over-
view of health outcomes of patients with a NFA using 
a conceptual HR-QoL model i.e. the Wilson and Cleary 
model [9]. A concrete conceptualization of the health out-
comes of patients with a NFA will be helpful in the under-
standing of the observed variety in HR-QoL outcomes, the 
identification of potential interventions, and can be used 
for further improvement of the clinical care trajectory and 
somatic and psychosocial guidance of these patients.
Health‑related quality of life
Over the past decade, alongside the improved treatment 
options, the scope of relevant outcomes has expanded 
from primary outcomes, such as mortality and morbidity, 
towards the evaluation of functional status and HR-QoL. 
Although it is established that HR-QoL should cover phys-
ical-, psychological-, and social well-being (in accordance 
with the biopsychosocial model) [10], a single concrete 
definition of HR-QoL is lacking, which results in major 
challenges for the evaluation and interpretation of HR-
QoL [11]. A commonly used definition is that HR-QoL 
is “the functional effect of an illness and its consequent 
therapy upon a patient, as perceived by the patient” [12]. 
For the assessment of HR-QoL several measures have been 
developed and validated, and it is recommended that a 
generic measure (covering general HR-QoL domains) is 
combined with a disease-specific measure (covering HR-
QoL aspects relevant for a specific disease) [11]. Unfortu-
nately, a disease-specific HR-QoL questionnaire for NFA 
is currently lacking.
The Wilson–Cleary model of HR‑QoL
A model that is frequently used to conceptualize HR-QoL, 
which validity is supported by empirical evidence over the 
years [13], and has been widely applied to different patient 
populations [14–16], is the conceptual model proposed 
by Wilson and Cleary (1995) [9]. This model establishes 
the biopsychosocial model [10] by integrating the clinical 
paradigm (i.e. the biomedical paradigm), and the quality 
of life model (i.e. social science paradigm). Where the 
biomedical paradigm focusses on biological, physiologi-
cal, and clinical outcomes, the social science paradigm 
focusses on dimensions of functioning and overall well-
being. The Wilson and Cleary model states that health can 
be considered as a continuum of increasing biological, 
psychological and social complexity, with pure biological 
measures on the left side of the model, and measures of 
general health perceptions on the right (Fig. 2). It clari-
fies the proposed dominant causal relationships (bold) and 
mediating factors. From left to right, it goes from cell-level 
to the individual, to the interaction of the individual in its 
social context. The arrows used in Fig. 2 do not imply that 
there are no reciprocal relations, just as the absence of 
arrows does not imply that there are no such relationships. 
Furthermore, it should be noted that the relation between 
symptom status and biological and physiological variables 
is rather complex. In other words, biological and physi-
ological variables can be profoundly abnormal without the 
patient perceiving symptoms, or the other way around. In 
the next paragraphs the Wilson and Cleary model will be 
elaborated for patients with a NFA.
Biological and physiological variables
Pituitary dysfunction may occur in all pituitary adenomas 
due to a variety of causes e.g. mass effect of the tumour, 
surgical treatment, or radiotherapy. Severe hormone defi-
cits, (pan)hypopituitarism, is diagnosed by blood sampling 
for gonadotropin, thyroid stimulating hormone, and pro-
lactin, and dynamic stimulation tests for adrenocortico-
trope hormone (ACTH), cortisol and growth hormone, 
and measurement of urine production for vasopressin 
deficiency [17]. Mild hypopituitarism can be difficult to 
diagnose, due to individual set-points, hormone sensi-
tivity, and circadian variability. Nevertheless, also mild 
hypopituitarism may affect end organ function. Therefore, 
the majority of the patients with hypopituitarism need 
lifelong hormone replacement therapy, aiming to mimic 
the physiology of end organ hormones as good as pos-
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Fig. 1  HR-QoL scores of patients with a NFA (Short Form 36 
scores), figure derived from [4]. Higher scores indicate better HR-
QoL
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of particular relevance, since too low cortisol levels can 
lead to a potentially life threatening acute adrenal crisis 
(i.e. Addison’s crisis). Contrary to this, when replacement 
therapy exceeds supra-physiological cortisol levels, it can 
result in Cushing’s syndrome like symptoms. Therefore, 
adequate replacement therapy in adrenal insufficiency as 
well as, adaptation of the dose during stress, is crucial 
[18]. In clinical practice, endocrine diseases are followed 
by evaluating clinical signs and hormone measurements. 
Serum, plasma, salivary, or urinary hormone concentra-
tions are currently the best tools for clinicians to classify 
disease status in (chronic) care. It has been acknowledged 
that the currently available physiological measures do 
not always reliably represent the clinical situation. The 
assessment of cortisol levels in scalp hair is a relatively 
new method to assess cortisol exposure over longer time 
periods and has been evaluated in patients with primary 
and secondary adrenal insufficiency [19]. Furthermore, it 
was examined whether hair cortisol levels correlated with 
patient reported HR-QoL, and it appeared that HR-QoL 
correlates slightly with hair cortisol levels [20]. These 
results are not surprising, considering the Wilson–Cleary 
model with biological and physiological variables on the 
one end, and HR-QoL on the other end with patient- and 
environmental characteristics influencing this continuum. 
These observations support the idea that HR-QoL is not 
only determined by biological disease status, but by a mul-
tidimensional underlying mechanism.
Symptom status
When changes in biological and physiological variables 
occur, an individual might perceive this via symptoms. 
Symptom status is defined by Wilson and Cleary as a 
patient’s perception of an abnormal physical, emotional, or 
cognitive state [9]. As was mentioned previously, NFAs are 
usually relatively large at time of diagnosis, giving either 
compression on the pituitary or the optic chiasm, result-
ing in headaches, hypopituitarism, visual loss, third nerve 
palsy, pituitary apoplexy, tiredness, decreased libido, and 
sometimes even galactorrhoea [3]. These symptoms tend 
to improve after surgery, however, extensive longitudinal 
literature of perioperative HR-QoL is limited. Wolf et al. 
demonstrated that headache severity and vision related 
HR-QoL improved significantly up to 6 months after trans-
sphenoidal surgery [21]. Furthermore, patients may suf-
fer from impaired olfactory function as a complication of 
the transsphenoidal surgery. Little et al. showed an initial 
decrease of sinonasal HR-QoL after (both microscopic and 
endoscopic) surgery, which improved at later follow-up 
[22]. Wang et al. demonstrated a decrease in the ability to 
Fig. 2  Wilson–Cleary model of HR-QoL [9]. Biological and physi-
ological variables: function of cell, organs, and organ systems e.g. 
diagnoses, laboratory values, measures of physiological function, and 
physical examination findings. Symptom status: a patient’s percep-
tion of an abnormal physical, emotional or cognitive state. Functional 
status: ability of the individual to perform particular tasks. The main 
domains of functioning are physical functioning, social functioning, 
role function, and psychological function. General health perceptions: 
subjective rating of health, and represent and integrates all the previ-
ous health concepts
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detect odours up to 4 months after surgery [23]. Although 
symptoms improve after biomedical treatment, persistent 
symptoms are reported after long-term remission. During 
focus group conversations with patients in a chronic state of 
their disease, patients reported physical pain, sleeping prob-
lems, changes in physical appearance (i.e. weight changes), 
cognitive problems (i.e. problems in concentration, short-
term memory, and executive functioning), decreased libido, 
physical sexual dysfunction, depressive symptoms, melan-
choly, mood swings, worries, increased sensitivity to stress, 
fear of tumour recurrence, decreased self-esteem, loneliness, 
anger, difficulties in communication about the disease, and 
a lack of empathy from the environment. The reported sleep 
problems were characterized by sleeping in blocks of 2–3 h 
[24]. Sleep characteristics have also been quantitatively 
examined, showing sleep alterations in patients treated 
for a NFA, including decreased subjective sleep quality, 
disturbed distribution of sleep stages and disturbances in 
diurnal rhythmicity [6, 25]. Although it can be postulated 
that these sleeping problems can be explained by imperfec-
tions in hormone replacement therapy (i.e. hydrocortisone 
replacement) [26], there is increasing evidence that these 
problems are caused by hypothalamic dysfunction [27]. Jou-
stra et al. examined sleep characteristics in patients treated 
for a NFA and patients with primary adrenal insufficiency 
treated with hydrocortisone replacement therapy and dem-
onstrated that patients with primary adrenal insufficiency 
have normal sleep characteristics in contrast to patients with 
a NFA. These results provided evidence that sleeping prob-
lems might be caused by hypothalamic dysfunction [28]. 
Furthermore, sleep disturbances and daytime sleepiness 
were also associated with increased impairment in HR-QoL 
[6, 29].
Functional status
This refers to the ability of the patient to perform particular 
defined tasks [9]. The symptom status largely determines 
whether patients perceive issues in their functioning. In 
accordance, the previously described symptoms result into 
impairments in several functional domains. During the focus 
group conversations patients reported problems in physi-
cal functioning, cognitive functioning, sexual functioning, 
psychological functioning, and social functioning. For 
instance, work related problems, such as diminished abil-
ity to function, to cooperate and to concentrate. As a result 
patients lost their job or were (partly) rejected [24]. The 
cognitive complaints reported by patients have also been 
examined through neuropsychological tests. Previous stud-
ies demonstrated that patients treated for NFA had a worse 
performance on verbal memory and executive functioning 
compared to healthy matched controls and references values 
[30, 31]. Interestingly, some reported the negative effect of 
additional radiotherapy on cognitive functioning [17, 30, 
32], while others did not [33, 34].
Characteristics of the individual
These individual characteristics (or patient characteristics) 
as formulated in the Wilson–Cleary model cover factors 
such as personality, motivation, values, and preferences. 
Patients’ preferences or values refer to the value patients 
attach to a particular consequence of their disease. For 
instance, a patient can experience a symptom as a burden, 
while the same symptom does not bother another patient. 
The way patients perceive their illness and its treatment 
are also known as ‘illness perceptions’ and ‘beliefs about 
medication’.
Illness perceptions and beliefs about medication
Illness perceptions and beliefs about medication are for-
mulated by the extended Common-Sense Model of Self-
Regulation (CSM) and can be categorised into values and 
preference in the Wilson–Cleary model. These preferences 
and values play an important role at several points of the 
Wilson–Cleary model and are particularly important in the 
understanding of general health perceptions and overall HR-
QoL, which is in accordance with the extended CSM, since 
this model also states that illness perceptions and beliefs 
about medication correlate with HR-QoL [35]. During the 
focus group conversations patients reported negative illness 
perceptions, such as the chronic time course of their disease, 
and concerns about potential side effects of their medication 
(i.e. hydrocortisone) [24].
Coping strategies
Furthermore, following the extended CSM, illness percep-
tions and beliefs about medicines influence coping behav-
iour. During the focus group conversations patients reported 
less efficient coping strategies, such as withdrawal, and over-
doing activities [24]. Coping strategies were also quantita-
tively assessed by Tiemensma et al. as they demonstrated 
that patients with pituitary disease use less effective cop-
ing strategies compared to an a-select sample of the Dutch 
population, including performing less active coping, seeking 
less social support, and using more avoidant coping strate-
gies [36].
Personality
A changed personality, another characteristic of the indi-
vidual, is considered a problem by patients. Sievers et al. 
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quantitatively examined personality traits in patients with a 
NFA, and demonstrated that compared to a normal popula-
tion control group, patients with a NFA reported more neu-
roticism, social desirability, anticipatory worries, pessimism, 
fear of uncertainty, fatigability, and asthenia [37]. Individual 
demographic characteristics have also been found to play a 
role in HR-QoL in patients with a NFA, since female sex 
and older age were found to negatively influence HR-QoL 
[5, 7, 33].
Characteristics of the environment
Economical-, psychological-, and social support, are envi-
ronmental characteristics. The latter two play an important 
role in general health perception and overall quality of life.
During the focus group conversations patients reported 
unmet needs regarding care and guidance they had per-
ceived. For instance, they would have received more infor-
mation about adverse effects of medication, physical-, psy-
chological-, and cognitive complaints and issues regarding 
sexual functioning. Furthermore, they would have preferred 
more recognition for certain complaints. These unmet needs 
can be categorised into characteristics of the individual (i.e. 
patient characteristics), since they can be influenced by 
personal factors. On the other hand, unmet needs can also 
be influenced by characteristics of the environment (e.g. 
availability of healthcare facilities). For example, patients 
reported dissatisfaction with other aspects of medical care 
i.e. stress-management training, lifestyle recommendations, 
physiotherapists, dietitians, medical sports experts, and psy-
chologists. For instance, these unmet needs can be caused 
by limitations in economic support or inadequate referrals. 
Some types of support (e.g. psychological-, social support) 
are less well developed for a rare disease such as pituitary 
disease compared to more prevalent (chronic) diseases.
Tools to meet unmet healthcare needs
Recently, a disease-specific patient reported outcome meas-
ure (PROM) was developed and validated by our research 
group, that assesses to which extent patients with pituitary 
disease are bothered by certain complaints, as well as their 
needs for support from healthcare professionals, i.e. the 
Leiden Bother and Needs Questionnaire for Pituitary dis-
ease (LBNQ-Pituitary)). This PROM covers five subscales 
i.e. mood problems, negative illness perceptions, issues in 
sexual functioning, physical and cognitive complaints, issues 
in social functioning [38]. This PROM can help healthcare 
professionals to address the unmet needs experienced by 
patients.
Besides professional environmental factors (i.e. health-
care facilities), there are also personal environmental factors. 
Often the single most important person in a patient’s social 
network is their spouse or partner. Focus group conversa-
tions with partners of patients with a pituitary condition 
revealed that partners were worried about the complaints of 
the pituitary disease, had negative beliefs about medication, 
and perceived coping challenges, relationship issues, social 
issues, and unmet needs regarding care [39]. These observa-
tions clearly demonstrate that chronic care for patients with 
pituitary disease is not limited to just the patient. In order to 
support patients and their partners in coping with the conse-
quences of the pituitary disease, a self-management program 
was developed for patients with pituitary disease and their 
potential partners i.e. Patient and Partner Education Pro-
gram for Pituitary disease (PPEP-Pituitary). This program 
aims to (at least partly) fulfil the unmet needs regarding sup-
port for psychological and social issues. PPEP-Pituitary was 
based on a standardized Patient and Partner Education Pro-
gram initially developed for patients (and partners) with Par-
kinson’s disease [40]. A multicenter randomized-controlled 
trial revealed that patients reported more self-efficacy after 
PPEP-Pituitary which was still present after 6 months. Self-
efficacy is described in the ‘Social Cognitive Theory’ of 
Bandura [41] and is defined as the person’s beliefs in his or 
her own capabilities and skills to perform a certain action, in 
a certain situation. Following this theory, behavior is directly 
influenced by goals and self-efficacy beliefs. In accordance, 
several studies showed that self-efficacy beliefs influences 
self-management behavior [42, 43]. Patients also reported 
to be less bothered by mood problems directly after PPEP-
Pituitary, however this returned to baseline levels 6 months 
later. Partners reported an increase in vitality, a decrease 
in depressive symptoms and an increase in treatment con-
trol after PPEP-Pituitary. This persisted at follow up after 
6 months [44]. It can be postulated that offering this pro-
gram as standard clinical care will improve the quality of 
the (healthcare) environment, and ultimately the patient and 
partner reported HR-QoL.
General health perceptions and HR‑QoL
In accordance to the Wilson–Cleary model, the domains 
described in the preceding paragraphs all contribute to 
patient perceived HR-QoL. This increase in interest in HR-
QoL has led to an increase in the number of HR-QoL studies 
in patients with a NFA and these studies show some diver-
sity regarding HR-QoL outcomes. Johnson and colleagues 
reported HR-QoL impairments in patients with an untreated 
NFA, especially in physical and mental functioning during 
active disease [45]. Some confirmed this decreased HR-
QoL in patients treated for a NFA compared to reference 
values and healthy controls [5, 6], however others did not 
report any differences [7, 8, 46]. Furthermore, some studies 
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demonstrated the negative effect of tumour recurrence [7], 
hypopituitarism [5, 47] and radiotherapy [48] on HR-QoL, 
while other did not (pituitary deficiency [46], radiotherapy 
[33, 46]). In addition, no differences in HR-QoL were found 
between patients surgically treated for a NFA and patients 
treated with mastoid surgery [48]. No differences were found 
while comparing patients with growth hormone deficiency 
(GHD) due to a NFA compared to traumatic brain injury 
[49, 50]. Male patients with GHD due to a NFA, compared 
to patients with GHD due to a craniopharyngioma, reported 
a better HR-QoL, whereas female patients with a NFA 
reported a worse HR-QoL [51]. Intervention studies reported 
that HR-QoL of patients with a NFA improved after trans-
sphenoidal surgery [47, 52]. Furthermore, patients treated 
with craniotomy reported more HR-QoL impairments com-
pared to patients treated with transsphenoidal surgery [8]. 
There have been several systematic reviews on endoscopic 
and microscopic transsphenoidal surgery, describing com-
parable or better clinical results after endocopic surgery 
[53]. Furthermore, a qualitative study performed by Lwu 
et al. described that patients perceived less burden after 
endoscopic surgery compared to microscopic surgery [54]. 
However, there is limited knowledge about the long-term 
outcomes of endoscopic vs. microscopic surgery in terms 
of HR-QoL. Intervention studies about the effect of growth 
hormone replacement therapy in patients treated for NFA 
with GHD all reported a positive effect on HR-QoL [49–51, 
55–57]. On the other hand, a cross-sectional study of Capat-
ina et al. demonstrated that non-replaced GHD was an inde-
pendent predictor of a better score in bodily pain, general 
health perception and energy/vitality [7].
Conclusion
The present review emphasizes that although patients may 
be in a stable medical condition, health issues are present at 
each level of the Wilson–Cleary model (Fig. 3). Application 
of the Wilson–Cleary model to patients with a NFA enables 
to observe that persistent impairments in HR-QoL might be 
explained by issues at each stage of this model. This also 
provides further insight into why there is such a variety in 
clinical outcomes, and why some patients experience severe 
problems, while others experience either no or only mild 
problems. This emphasises that improvement in overall 
HR-QoL in patients with pituitary disease requires optimal 
biomedical treatment initiating a cascade of improvement 
in health outcomes starting with a better symptom status. 
Nevertheless, this model also clarifies that besides the cur-
rently available biomedical interventions (i.e. surgery, radio-
therapy, hormone replacement therapy) targeting biological 
and physiological variables, interventions are needed that 
Fig. 3  Wilson–Cleary model of HR-QoL elaborated for NFA
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pay attention to other (psychosocial) elements of the model 
e.g. cognitive functioning, sexuality/intimacy, psychologi-
cal well-being, social functioning, coping behaviour, self-
efficacy beliefs, illness perceptions, medication beliefs, 
quality of the partner relationship, and the social network/
support. Therefore, further improvement of HR-QoL should 
be supported by a pituitary specific care trajectory, including 
psychosocial care (e.g. self-management training), in order 
to beneficially affect characteristics of the patient and the 
(healthcare) environment, with the utmost goal to optimize 
HR-QoL in patients after treatment for a NFA.
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